Trial · NCT06149286
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286, Phase 3, Recruiting, Regeneron Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma. Trials, record NCT06149286. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06149286
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- NCT number
- NCT06149286
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 580 participants, estimated
- Lead sponsor
- Regeneron Pharmaceuticals
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
- Interventions
- Odronextamab, Lenalidomide, Rituximab
- First posted
- 2023-11-28
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide | Up to 35 days | Part 1 |
| Primary | Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide | Up to 2 years | Part 1 |
| Primary | Severity of TEAEs for odronextamab in combination with lenalidomide | Up to 2 years | Part 1 |
| Primary | Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR) | Up to 5 years | Part 2 |
| Secondary | Odronextamab concentrations in serum | Up to 30 months | Part 1 and Part 2 |
| Secondary | Incidence of Anti-Drug Antibodies (ADA) to odronextamab | Up to 30 months | Part 1 and Part 2 |
| Secondary | Magnitude of ADAs to odronextamab | Up to 30 months | Part 1 and Part 2 |
| Secondary | Best Overall Response (BOR) as assessed by investigator review | Up to 30 months | Part 1 and Part 2 |
| Secondary | Duration of Response (DOR) as assessed by investigator review | Up to 5 years | Part 1 and Part 2 |
| Secondary | PFS as assessed by investigator review | Up to 5 years | Part 1 and Part 2 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06149286
GET https://conductscience.org/api/trials/v1/NCT06149286/registered?page=2